Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Rheumatol Rep. 2003 Oct;5(5):350-6.

B cell depletion therapy in systemic lupus erythematosus.

Author information

  • 1Department of Medicine: Immunology and Rheumatology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA. jennifer_anolik@urmc.rochester.edu

Abstract

There is a growing body of experimental evidence that B lymphocytes play a central role in the pathogenesis of systemic lupus erythematosus (SLE). B cells are, by definition, the precursors of antibody-secreting cells, and thus are the source of pathogenic autoantibodies. However, recent data indicate that B cells are not merely the passive producers of immunoglobulins, but also play a central role in autoimmunity via nonconventional mechanisms, including autoantigen presentation and modulation of other immune cells. Thus, B lymphocyte depletion has recently emerged as a promising therapeutic approach to the treatment of autoimmune diseases, including SLE. Rituximab is a chimeric mouse-human monoclonal antibody against the B cell-specific antigen CD20, which selectively and profoundly depletes B lymphocytes and has been widely used to treat B cell lymphomas. Recent open-label studies indicate that rituximab is safe and may be efficacious in the treatment of SLE, and continued study with randomized clinical trials is justified.

PMID:
12967516
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk